#Neotorch - Twitter Hashtag

over 2 years ago

@JAMANetworkOpen #NEOTORCH study #lcsm ➡️ Toripalimab + chemo 📈 in EFS vs chemo alone in resectable #NSCLC IMHO: Open ❓s: 1) No. of cycles pre-op: 3 vs 4? 2) Value of addnl #ICI in pCR/MPR? Only 70% pts get to #maintenance Rx https://t.co/omz2H39xcr @OncoAlert @LungCancerRx

ADesaiMD's tweet photo. @JAMANetworkOpen #NEOTORCH study #lcsm
➡️ Toripalimab + chemo 📈 in EFS vs chemo alone in resectable #NSCLC
IMHO: Open ❓s:
1) No. of cycles pre-op: 3 vs 4?
2) Value of addnl #ICI in pCR/MPR? Only 70% pts get to #maintenance Rx https://t.co/omz2H39xcr @OncoAlert @LungCancerRx https://t.co/F93dbzvvA9

0

22

7

3

3K

Martín Lázaro @mlazqui

about 3 years ago

‼️Estudios #Keynote671 y #Neotorch: tratamiento perioperatorio en cáncer de pulmón no microcítico #lcsm #nsclc #pembrolizumab #toripalimab ➡️En @onconius https://t.co/mO8l5a1bPp 🙋‍♂️@OncoLucus y @mlazqui

0

2

1

775

Oncology for the Inquisitive Mind @InquisitiveOnc

over 3 years ago

*ASCO episode 5* early #lungcancer #ASCO23 confirmed lung cancers days of high recurrence are numbered with toripalimab, relatlimab and novel agent BI764532. #Neotorch #Neopredict #BI764532 Abstract links in the episode description below: https://t.co/ZBwxH3bLMi

1

2

0

527

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 3 years ago · Chicago

#ASCO23 @ASCO #NEOTORCH ✨Tori + chemo improved EFS ✨ MPR 48.5%, pCR 24.8% ✨ benefit across PDL1 subgp #LCSM @OncoAlert @LungCancerRx

CharuAggarwalMD's tweet photo. #ASCO23 @ASCO
#NEOTORCH
✨Tori + chemo improved EFS
✨ MPR 48.5%, pCR 24.8%
✨ benefit across PDL1 subgp
#LCSM @OncoAlert @LungCancerRx https://t.co/HtGaLDHcex

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 3 years ago

#ASCO23 @ASCO Abs#8501 Data up next! #Perioperative Therapy Tori (aPDL1) + chemo vs. chemo in neo-adj setting prior to surgery for II/III #NSCLC #LCSM

0

1

0

24K

0

14

8

1

12K

Aakash Desai @ADesaiMD

over 3 years ago

#ASCO23 @Oncoalert @LungCancerRx 📚 #NEOTORCH: perioperative toripalimab/chemo vs chemo in resectable #LCSM Toripalimab arm showed significant improvement in EFS ⏳. 🆙MPR and pCR rates also observed with toripalimab 💊 Safety profile was ?manageable, despite more irAEs 👍.

0

19

8

1

8K

Aakash Desai @ADesaiMD

over 3 years ago

#ASCO23 @Oncoalert @LungCancerRx 📚 #NEOTORCH: perioperative toripalimab/chemo vs chemo in resectable #LCSM Toripalimab arm showed significant improvement in EFS ⏳. 🆙MPR and pCR rates also observed with toripalimab 💊 Safety profile was ?manageable, despite more irAEs 👍.

0

9

3

2

1K

Oncology Brothers

@OncBrothers

over 3 years ago

#AACR23 highlights from our community oncology perspective: 1. #AEGEAN (#NEOTORCH - @ASCO #ASCOPlenarySeries) 2. #Keynote966 3. @SWOG #S1512 Also on: - https://t.co/yvADXtMOZW - “Oncology Brothers” podcast🎙 #OncTwitter #MedTwitter @OncoAlert @HemOncFellows @AACR #Oncology

0

49

17

3

7K

Drew Moghanaki

@DrewMoghanaki

over 3 years ago

DRUM ROLL: Within a week of learning AEGEAN's results, a 3rd randomized phase III trial demonstrates the benefit of adding a PD-1 inhibitor to platinum-based neoadjuvant chemotherapy. This time, the pCR rate = 25%. #Neotorch #ASCO23

DrewMoghanaki's tweet photo. DRUM ROLL: Within a week of learning AEGEAN's results, a 3rd randomized phase III trial demonstrates the benefit of adding a PD-1 inhibitor to platinum-based neoadjuvant chemotherapy. This time, the pCR rate = 25%. #Neotorch #ASCO23 https://t.co/4IJnrAyX2r

2

57

10

16

17K

Targeted Oncology @TargetedOnc

over 3 years ago

The 3 #Neotorch trial is the first to show an event-free survival advantage with immunotherapy for lung cancer. An event-free survival improvement was demonstrated in resectable #NSCLC patients. #lcsm https://t.co/ouIiCEX9ZT

0

2

0

420